Systemic treatment of Kaposi's sarcoma: current status and future directions.
Lilenbaum
R C
RC
Ratner
L
L
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D015696:Gene Products, tat / Q000037:antagonists & inhibitors; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D012514:Sarcoma, Kaposi / Q000188:drug therapy*; D054322:tat Gene Products, Human Immunodeficiency Virus
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D015696:Gene Products, tat; D016298:Hematopoietic Cell Growth Factors; D007155:Immunologic Factors; D007376:Interleukin-2; D054322:tat Gene Products, Human Immunodeficiency Virus; D007372:Interferons